← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT06527495

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition HCC
Sponsor Assiut University
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2023-01-01
Completion 2024-12-01
Interventions
Sorafenib

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.

Eligibility Criteria

Inclusion Criteria: * Age of all studied subjects ≥ 18 years old * All patients with hepatocellular carcinoma will be included in group I. * Patients not treated with systemic TKIs Exclusion Criteria: * Patients presented with liver tumors other than HCC. * Patients with Child-Pugh grade C for liver function. * Patients with other malignancies. * Patients with chronic inflammatory disorders. * Patients with severe organ dysfunction such as heart, lung, and kidney. * Patients who cannot tolerate or are allergic to sorafenib. * Patients with severe coagulation dysfunction were uncorrectable. * Age less than 18 years old.

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE HCC TRIALS
}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology